ClinicalTrials.Veeva

Menu

A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)

Kissei logo

Kissei

Status and phase

Completed
Phase 3

Conditions

Anemia

Treatments

Drug: Darbepoetin alfa
Drug: JR-131

Study type

Interventional

Funder types

Industry

Identifiers

NCT02912494
JR-131-301

Details and patient eligibility

About

The purpose of this study is to investigate the equivalence of JR-131 to Darbepoetin alfa and evaluate the safety of JR-131 in renal anemia patients with chronic kidney disease (CKD).

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients being treated with Darbepoetin alfa.

Exclusion criteria

  • Patients having complication or history of a cardiovascular / lung / brain infarction.
  • Patients having a pronounced hemorrhagic lesion.

Trial design

0 participants in 2 patient groups

JR-131
Experimental group
Treatment:
Drug: JR-131
Darbepoetin alfa
Active Comparator group
Treatment:
Drug: Darbepoetin alfa

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems